Why the study?
Does genetic testing reduce the incidence of anthracycline-induced cardiotoxicity?
Does genetic testing reduce the incidence of anthracycline-induced cardiotoxicity?
Genetic testing may improve risk stratification and prevention of anthracycline-induced cardiotoxicity.
May refine anthracycline cardiotoxicity risk stratification; extends genetic evidence for precision cardio-oncology.
Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.
No takes yet. Share an insight, caveat, or question.
Aminkeng et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: